Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christy A. Sasiela"'
Autor:
Christy A. Sasiela, Yili Yang, David Stewart, Jirouta Kitagaki, Pankaj Oberoi, John A. Beutler, Yassamin J. Safiran, Ilia Davydov, Allan M. Weissman, James B. McMahon, Barry R. O'Keefe, Ekaterina I. Goncharova
Publikováno v:
SLAS Discovery. 13:229-237
High-throughput screening technologies have revolutionized the manner in which potential therapeutics are identified. Although they are the source of lead compounds for ~65% of anticancer and antimicrobial drugs approved by the Food and Drug Administ
Autor:
Y. Yang, John A. Beutler, Christy A. Sasiela, Barry R. O'Keefe, Jirouta Kitagaki, Allan M. Weissman
Publikováno v:
The Ubiquitin System in Health and Disease ISBN: 9783540851066
The ubiquitin conjugating system represents a rich source of potential molecular targets for cancer and other diseases. One target of great interest is the RING finger ubiquitin ligase (E3) Hdm2/Mdm2, which is frequently overexpressed in cancer and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d1b0c13e78b3cdc62724835dd32174c
https://doi.org/10.1007/2789_2008_108
https://doi.org/10.1007/2789_2008_108
Publikováno v:
The Journal of biological chemistry. 283(8)
E-cadherins play an essential role in maintaining epithelial polarity by forming Ca2+-dependent adherens junctions between epithelial cells. Here, we report that Ca2+ depletion induces E-cadherin ubiquitination and lysosomal degradation and that Cdc4
Publikováno v:
Peptides: The Wave of the Future ISBN: 9789401039055
Despite significant research advances, breast cancer is still the second leading cause of cancer deaths among American women [1]. Thus, new therapeutic modalities are desperately needed with different mechanisms of action from those currently availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1efef4b4d605334e6d9efcd2276d00bd
https://doi.org/10.1007/978-94-010-0464-0_375
https://doi.org/10.1007/978-94-010-0464-0_375
Publikováno v:
Peptides: The Wave of the Future ISBN: 9789401039055
We previously reported a novel kappa opioid receptor antagonist JVA 901, now named venorphin, which was designed as a chimeric construct of a cobra venom tetrapeptide and [D-Ala8]dynorphin A(1–11)NH2 [1]. The N-terminal region of this new peptide e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9fee3f79dfa19eb0564e1707c91ae36
https://doi.org/10.1007/978-94-010-0464-0_321
https://doi.org/10.1007/978-94-010-0464-0_321